Leerink Partnrs Estimates Shattuck Labs FY2024 Earnings

Shattuck Labs, Inc. (NASDAQ:STTK) – Analysts at Leerink Partnrs issued their FY2024 earnings estimates for shares of Shattuck Labs in a report released on Monday, March 17th. Leerink Partnrs analyst F. Khurshid forecasts that the company will post earnings per share of ($1.42) for the year. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Shattuck Labs’ current full-year earnings is ($1.48) per share. Leerink Partnrs also issued estimates for Shattuck Labs’ Q4 2024 earnings at ($0.30) EPS, Q1 2025 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($0.93) EPS and FY2026 earnings at ($0.93) EPS.

Separately, Leerink Partners initiated coverage on shares of Shattuck Labs in a report on Monday, March 17th. They set an “outperform” rating and a $4.00 target price on the stock. Four research analysts have rated the stock with a hold rating, one has issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $7.50.

Shattuck Labs Stock Up 3.4 %

Shares of STTK opened at $1.20 on Thursday. The firm has a market cap of $57.29 million, a PE ratio of -0.78 and a beta of 1.66. The company’s fifty day moving average is $1.24 and its two-hundred day moving average is $1.58. Shattuck Labs has a fifty-two week low of $0.94 and a fifty-two week high of $11.76.

Hedge Funds Weigh In On Shattuck Labs

Several hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC lifted its holdings in shares of Shattuck Labs by 0.4% during the 3rd quarter. FMR LLC now owns 7,159,090 shares of the company’s stock valued at $24,985,000 after acquiring an additional 26,460 shares in the last quarter. Prosight Management LP lifted its holdings in Shattuck Labs by 15.1% in the 4th quarter. Prosight Management LP now owns 6,638,935 shares of the company’s stock worth $8,033,000 after buying an additional 873,409 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in Shattuck Labs by 61.2% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 4,675,000 shares of the company’s stock worth $5,657,000 after buying an additional 1,775,000 shares in the last quarter. 683 Capital Management LLC acquired a new position in Shattuck Labs in the 4th quarter worth $1,270,000. Finally, Geode Capital Management LLC lifted its holdings in Shattuck Labs by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 912,202 shares of the company’s stock worth $3,184,000 after buying an additional 8,133 shares in the last quarter. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.